HRA Pharma eagerly seeking acquisitions
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
HRA Pharma is aggressively seeking out acquisitions to help it become one of the fastest-growing OTC companies in the world, according to the firm’s president and chief executive officer David Wright.
You may also be interested in...
HRA Pharma Reveals Big Growth Ambitions In Quest To Become Top-10 OTC Player
A combination of prescription-to-OTC switches, acquisitions and maximising the potential of its existing portfolio will take France’s HRA Pharma to the next level, reveals chief commercial officer Martyn Hilton.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.